8,165 reports of this reaction
14.3% of all MEDROXYPROGESTERONE ACETATE reports
#2 most reported adverse reaction
BREAST CANCER is the #2 most commonly reported adverse reaction for MEDROXYPROGESTERONE ACETATE, manufactured by Pharmacia & Upjohn Company LLC. There are 8,165 FDA adverse event reports linking MEDROXYPROGESTERONE ACETATE to BREAST CANCER. This represents approximately 14.3% of all 57,188 adverse event reports for this drug.
Patients taking MEDROXYPROGESTERONE ACETATE who experience breast cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER is a frequently reported adverse event for MEDROXYPROGESTERONE ACETATE, accounting for a significant proportion of all reports.
In addition to breast cancer, the following adverse reactions have been reported for MEDROXYPROGESTERONE ACETATE:
The following drugs have also been linked to breast cancer in FDA adverse event reports:
BREAST CANCER has been reported as an adverse event in 8,165 FDA reports for MEDROXYPROGESTERONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER accounts for approximately 14.3% of all adverse event reports for MEDROXYPROGESTERONE ACETATE, making it one of the most commonly reported side effect.
If you experience breast cancer while taking MEDROXYPROGESTERONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.